1. High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents
- Author
-
Jianpeng Ma, Zidong Yang, Xu Liu, Hongyan Ding, Mingyuan Liu, Qiang Dong, Yinting Zhou, Yang Zhou, Qianyun Liu, Kai Chen, Haibo Wu, Zezhi Li, Yongkang Zhang, Xiaowei Mao, Zhuqing Shi, Huihui Lv, and Yan Han
- Subjects
medicine.medical_specialty ,Aspirin ,Neurology ,business.industry ,General Neuroscience ,CYP2C19 ,Vascular surgery ,Clopidogrel ,medicine.disease ,Internal medicine ,Clinical endpoint ,Medicine ,Neurology (clinical) ,Myocardial infarction ,Risk factor ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
The purpose was to explore the value of high on-treatment platelet reactivity (HTPR) in predicting long-term clinical outcomes for stroke patients. The platelet reactivity was assayed after being treated with either 75 mg clopidogrel or 100 mg aspirin daily with VerifyNow System in stroke patients. HTPR for clopidogrel was defined as PRU ≥ 208, and that for aspirin was defined as ARU ≥ 550. CYP2C19 genotyping was performed using the Sequenom MassARRAY iPLEX platform. The primary endpoint was a composite of recurrent ischemic stroke, transient ischemic attack, myocardial infarction, or ischemic vascular death. The safety endpoint was bleeding. In the clopidogrel group, among 345 patients recruited, 174 of them were categorized as HTPR. A total of 270 patients were followed up for 54 months. There was a significant association between HTPR and the primary endpoint (HRadj 2.13 [95% CI, 1.43–3.15], p
- Published
- 2021